Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of ...

GSK's main partner in the consumer health joint venture that became Haleon – Pfizer – holds the remaining 32% in the new company and has said that it will sell its stake now that the ...

Haleon said in a prospectus filed earlier this week that it could face "possible liabilities" connected with OTC Zantac, although it is in the midst of indemnity negotiations with GSK and Pfizer ...

She pointed to several other trials of methotrexate in both hand and knee OA that showed little to no benefit, and that in ...

Driven by self-medication trends, health-conscious consumers, and innovative formulations, the OTC drugs market thrives on the widespread availabilit ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...